The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

December 27, 2027

Study Completion Date

December 31, 2031

Conditions
Kidney CancerClear Cell Renal Cell Carcinoma MetastaticSynchronous Neoplasm
Interventions
PROCEDURE

Cytoreductive nephrectomy±metastasectomy

Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.

PROCEDURE

Cytoreductive nephrectomy±metastasectomy

Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.

OTHER

Human-derived materials sampling

Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Gangnam Severance Hospital, Seoul

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

NOT_YET_RECRUITING

Yongin Severance Hospital, Yongin-si

All Listed Sponsors
lead

Yonsei University

OTHER